Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

OBJECTIVES: To identify a therapeutic target interval for certolizumab pegol drug levels and examine the influence of anti-drug antibodies in patients with inflammatory joint diseases. METHODS: Certolizumab pegol and anti-drug antibody levels were measured in serum samples collected after 3 months o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Res Ther
Autors principals: Gehin, Johanna Elin, Goll, Guro Løvik, Warren, David John, Syversen, Silje Watterdal, Sexton, Joseph, Strand, Eldri Kveine, Kvien, Tore Kristian, Bolstad, Nils, Lie, Elisabeth
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883678/
https://ncbi.nlm.nih.gov/pubmed/31783773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-2009-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars